ARID1A and cancer: Given the widespread role of the SWI/SNF complex62, the frequency of ARID1A inactivation in several malignancies other than HCC62, and the availability of TEAD-YAP inhibitors53, the identification of the ARID1A-TEAD1 synthetic lethal pair provides an example of how SLIdR can help improve cancer therapy.